Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serum Sourcing Study for Menveo and Bexsero
NCT03493919Phase 4Completed
- Sponsor
- GSK
- Start
- Mar 2018
- Primary completion
- May 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 4, open-label trial of recombinant neisseria meningitidis group B nhba fusion protein and Meningococcal polysaccharide (serogroups A, C, W, and Y) tetanus toxoid conjugate vaccine in meningococcal meningitis (4 arms), sponsored by GSK. Primary endpoint: Number of Human Blood Samples Collected for Conversion Into Serum at Day 61. Started Mar 2018; status: completed.
02
Drugs
recombinant neisseria meningitidis group B nhba fusion proteinMeningococcal polysaccharide (serogroups A, C, W, and Y) tetanus toxoid conjugate vaccine
03
Conditions
meningococcal meningitis
Beyond the preview
Go deeper on NCT03493919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03493919.